[ Psychiatry Consortium ]

The Psychiatry Consortium is seeking project proposals which focus on the validation of novel molecular drug-targets for the following mental health conditions: psychotic disorders, bipolar disorder, depression, anxiety, stress-related disorders, PTSD, OCD, autism spectrum disorders as well as psychiatric symptoms associated with dementia and other cognitive disorders.

The Psychiatry Consortium intend to fund projects which:

• show some evidence that links the molecular target to human disease and of the target modulation having a therapeutic effect, which can be further developed or validated
• will enable tools for target validation e.g. through optimisation of existing tool compounds to improve selectivity, potency, bioavailability

• Applicants from academic institutions and other independent research institutes worldwide in collaboration with the Psychiatry Consortium members.
• Applications from small companies (micro and medium) may also be considered, as standalone or in collaboration with an academic institution or research institute.

• Projects will be expected to last up to 3 years and the total eligible funding will be between £200,000 and £1,000,000.
• The Psychiatry Consortium will cover 100% of eligible direct research costs associated with the project, including, for example, research funding for assay development, screening and medicinal/biopharmaceutical chemistry resources required to develop novel chemistry against the target, and salary support for the applicant themselves or for research staff as appropriate. This applies for both applications from academic institutions and SMEs.
• The Psychiatry Consortium will not fund indirect costs, such as non-specific estimated costs, including estates costs, library costs, finance, legal and HR costs.